Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) have received an average recommendation of “Buy” from the seven ratings firms that are currently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have covered the stock in the last year is $22.57.
Several research analysts recently issued reports on the company. HC Wainwright increased their price objective on Avadel Pharmaceuticals from $21.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, March 5th. UBS Group assumed coverage on Avadel Pharmaceuticals in a report on Tuesday, February 6th. They issued a “buy” rating and a $21.00 price objective for the company. Oppenheimer increased their target price on shares of Avadel Pharmaceuticals from $27.00 to $29.00 and gave the stock an “outperform” rating in a report on Tuesday, March 5th. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Avadel Pharmaceuticals in a research report on Tuesday, April 9th. Finally, Craig Hallum upped their price target on shares of Avadel Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th.
View Our Latest Stock Report on Avadel Pharmaceuticals
Avadel Pharmaceuticals Stock Performance
Avadel Pharmaceuticals (NASDAQ:AVDL – Get Free Report) last released its earnings results on Monday, March 4th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.04). The firm had revenue of $19.45 million during the quarter, compared to analyst estimates of $17.41 million. During the same period last year, the business posted ($0.44) EPS. As a group, equities analysts predict that Avadel Pharmaceuticals will post -0.46 EPS for the current year.
Hedge Funds Weigh In On Avadel Pharmaceuticals
Several institutional investors and hedge funds have recently bought and sold shares of the company. Quantbot Technologies LP purchased a new position in shares of Avadel Pharmaceuticals in the third quarter worth $78,000. Quarry LP purchased a new position in Avadel Pharmaceuticals in the 4th quarter worth $120,000. Claro Advisors LLC acquired a new stake in Avadel Pharmaceuticals during the 1st quarter worth about $172,000. China Universal Asset Management Co. Ltd. grew its stake in Avadel Pharmaceuticals by 349.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,327 shares of the company’s stock valued at $146,000 after purchasing an additional 8,029 shares during the last quarter. Finally, Exencial Wealth Advisors LLC acquired a new position in shares of Avadel Pharmaceuticals in the third quarter valued at about $124,000. 69.19% of the stock is owned by hedge funds and other institutional investors.
Avadel Pharmaceuticals Company Profile
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Further Reading
- Five stocks we like better than Avadel Pharmaceuticals
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Charles Schwab Fortifies its Uptrend on EPS Beat
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Lockheed Martin Stock Aims for a Fresh All-Time High
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.